
usd pm et
summari provid precis instrument analyt servic softwar use life scienc
industri retail applic
price-to-earnings oper ep
think benefit industri geograph
product diversif spread across life scienc
industri retail end-market help firm
maintain stabl cash flow one end-market
may experienc short-term weak view
also benefit strong reput product
qualiti innov custom servic softwar
integr think contribut sticki
custom also low leverag rel
peer averag see posit partial off-set
increas relianc life scienc industri china
sale growth
feb ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug pm stock trade
revenu grew yoy report yoy
local currenc lc laboratori product
total revenu led way lc
sale grow yoy robust
demand biopharma lab continu
newer applic
industri gene-bas therapi
immuno-oncolog continu rapidli expand
food retail howev signific
drag growth lc sale drop
impress abil
navig escal tariff environ
without notic impact oper
mare think speak
incom per share increas yoy
materi faster revenu strong
margin expans three percentag point
contribut share repurchas around
million year end june
expect sale grow around
next year econonm slowdown
europ present headwind see ep
growth remain strong price
power oper effici drive
percentag point gain oper
worthi premium valuat
view due excel price power
think driven high switch cost
popular labx softwar integr
cutting-edg precis instrument make
undesir custom switch
competitor view expect
share outperform market next
year howev think near full
price power evidenc steadi
upward trend pre-tax margin
year-end june
despit recent trade war without
major competit advantag also
appar pre-tax return invest capit
consist
think lead industri expect
except maintain futur
year continu invest
target ep
estim -- histor forward price-to-earnings
averag expect increas
strong price power risk view includ
potenti govern restrict sale
growth china slowdown
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview mettler-toledo intern inc suppli precis measur
analysi instrument servic use laboratori sale industri food retail
applic product servic critic custom life scienc industri
pharmaceut biotech compani well contract research organ food beverag
produc chemic specialti chemic cosmet compani food retail transport
logist industri metal industri electron industri academ commun
compani report oper five segment oper sale swiss
oper western european oper chines oper
product sever key product categori includ balanc pipett laboratori softwar
detail
laboratori balanc compani manufactur broad varieti laboratori balanc associ
analysi instrument weigh rang one ten-millionth gram kilogram
laboratori balanc primarili use pharmaceut biotechnolog test lab food chemic
cosmet academia industri
pipett pipett use laboratori dispens precis volum liquid compani
also maintain servic center key market custom period send pipett
certifi recalibr princip end market pipett pharmaceut biotech academia
analyt instrument product segment includ titrat measur chemic composit
sampl use environment research laboratori well qualiti control lab
pharmaceut food beverag industri thermal analysi system measur
materi properti function temperatur weight dimens energi flow viscoelast
properti use primarili plastic polym industri academia increasingli
pharmaceut industri ph meter densiti refractometri insrument moistur analyz
laboratori softwar labx compani pc-base laboratori embed softwar platform manag
analyz data gener balanc titrat ph meter moistur analyz
analyt instrument labx provid full network capabl assist workflow autom
enabl custom collect archiv data complianc food drug administr
fda traceabl requir electron store data
believ labx softwar largest market share analyt instrument softwar
packag research engin familiar labx high level integr laboratori
workflow make custom sticki view switch new instrument run
unfamiliar softwar would requir extens train costli effort updat workflow
gener separ sell softwar run competitor instrument softwar
embed hardwar product
industri weigh instrument offer comprehens line industri scale weigh
devic bench scale floor scale weigh modul weigh load gram
sever thousand kilogram industri weigh product use wide rang industri
applic count formul mix ingredi qualiti control
industri termin transport logist vehicl scale system softwar industri
termin allow collect data integr manufactur process help autom
also suppli automat dimension measur data captur solut integr
in-mot weigh dimens identif technolog solut custom
measur weight cubic volum packag appropri bill load manag qualiti
control also produc scale weigh truck railcar heavi industri scale capabl
measur weight ton permit accur weigh extrem environment condit
also provid softwar integr industri analysi product improv
workflow enhanc data collect analysi
corpor strategi histor highli acquisit like life scienc peer
period spent million acquisit versu averag
billion larg peer life scienc tool servic industri like thermo fisher agil
made two rel small acquisit last three year howev juli
compani acquir henri troemmer million novemb acquir biotix
million -base manufactur distributor plastic consum associ
pipett includ tip tube reagent reservoir use life scienc market
typic make limit small-scal acquisit prolif purchas share
compani made net repurchas impact share issuanc total
billion repurchas reduc share count three-year period
provid materi boost ep activ repurchas share price declin
view think indic manag adept term capit alloc
financi trend sale increas billion billion repres
three-year compound annual growth rate compound-annual-growth-rate period adjust pre-tax incom
per share grown three-year compound-annual-growth-rate earn growth outpac sale growth due
share repurchas well adjust pre-tax incom margin improv
indic excel price power view conserv capit
ebita-to-interest decemb
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
lst sub-industri
next year expect earn growth
remain posit slow sharpli
rate achiev posit
earn growth view
healthi fund public medic research
demand growth emerg market expect
factor balanc slower
biopharmaceut spend growth
neg effect trade tariff
budget nation institut
nih grow rapidli
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih
fy sep budget grew vs prior
year follow growth
fy fy respect mark
major acceler averag growth
fy fy believ
boost sale lst
sub-industri grew
expect lst firm
continu see strong demand
publicly-fund lab
prolifer advanc health care around
world also continu drive demand
growth lst firm trend
remain particularli strong china
emerg market rapidli grow middl
class gain access advanc health
care drive suppli need new expand
medic research lab facil
estim trend drove growth
lst sub-industri sale
asia-pacif region expect
continu posit long-term driver
contrast strong demand growth
expect publicly-fund client think
biopharmaceut firm moder
 spend growth year ahead
estim total
spend
biopharmaceut compani grew
annual averag expect slow
howev
mani biopharmaceut firm look limit
spend growth off-set recent
revenu headwind patent expir
public scrutini high drug price larg
swath biopharma typic flow
lst firm suppli depart
research tool softwar contract servic
accordingli think slowdown
biopharma growth reduc tailwind
mani lst firm receiv
client group recent year
final recent escal trade tariff
neg impact lst earn
growth view expect
continu analyt
instrument maker lst sub-industri
global suppli chain see
strong oper profit growth
first half brought lower profit
mani busi think shift
relat escal tariff impos
 -china trade
soften demand -made
instrument china rais product
cost instrument maker limit
suppli chain flexibl end sight
current trade disput expect tariff
continu pressur sale growth
oper margin sub-industri
year-to-d septemb
 life scienc tool
servic rose broader
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
above-averag futur growth underli fundament busi
remain strong lower opinion hold approxim
ytd return move share price valuat rang view fairli
valu last five year share trade averag forward price-to-earnings
multipl respect share valu
consensu ep estim think expens side
even consid grow price power instrument softwar
custom view increasingli sticki typic direct
free cash flow share repurchas elev valuat
repurchas diminish posit impact ep growth /colin scarola
et cfra keep buy opinion share
intern inc lift target
ep estim -- long-term forward price-to-earnings averag
see life scienc drive above-averag futur growth ep vs
beat consensu rais ep estim
start grew sale yoy organ growth
local currenc notabl despit new tariff sale growth china remain
robust yoy drove acceler growth asia region
sale yoy yoy encourag
abil pass tariff-rel price increas custom without
loss momentum think speak strength brand lack
meaning competit market like china oper continu improv
well sg yoy despit strong sale growth
price power oper effici continu worthi rel
high valuat view /colin scarola
analyst research note compani news
pm et cfra keep hold opinion share
intern inc keep target
ep estim -- within histor forward price-to-earnings averag rang drop
ep estim start
adjust ep beat consensu grew yoy
materi faster yoy revenu growth sale mix shift
higher margin product integr softwar view sale
growth laboratori total yoy industri yoy
partli off-set sharp declin food retail yoy food
retail gener substanti revenu groceri check counter scale
demand hurt trend toward on-line groceri shop
view howev see threaten long-term earn power
expect ep grow two larger segment experi healthi
demand growth particularli laboratori due strong biopharma demand
et cfra lower opinion health marketweight
overweight lower recommend exposur
sector marketweight overweight group tradit
perform well tradit lacklust summer month keep
pace overal market remaind year besid alreadi
trade elev valuat particularli best perform
sub-industri medic technolog life scienc tool think
group contend increas political/regulatori risk
presidenti elect cycl get full swing final group
below-averag percentag favor constitu invest recommend
et cfra keep hold opinion share
intern inc lift target
ep estim -- histor forward price-to-earnings averag expect
return capit increas strong price power rais ep
estim maintain ep vs
beat consensu broke streak yoy
higher revenu growth slowdown yoy laboratori sale
industri end-market continu see grow demand local currenc
lc sale growth yoy respect food retail
headwind sharp sale declin yoy lc despit top-lin
slowdown demonstr strength oper model view
adjust pre-tax margin improv basi point yoy drive
yoy gain pre-tax ep strong long-term outlook
integr instrument-softwar model neutral share due
expens valuat view /colin scarola
et cfra keep hold opinion share
intern inc keep target
ep estim -- long-term forward price-to-earnings averag expect
return capit increas strong price power ep vs
beat consensu maintain ep estim
sale grew yoy local currenc europ asia/rest world
combin revenu led way grow sale yoy local
currenc china particularli strong grow yoy think china
revenu total fairli insul potenti escal
trade war due primarili gener china-bas oper
export subject tariff expect
revenu grow around even recent tariff hike remain effect
year forecast ep growth see ep grow faster
sale strong price power oper effici produc
percentag point gain oper margin /colin scarola
pm et cfra lower view mettler-toledo intern inc share
hold buy maintain ep estim
target price ep estim -- higher
long-term forward price-to-earnings averag see life scienc custom drive
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
